thelancet.com
Switch to injectable cabotegravir–rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-we...
In adolescents with HIV with virological suppression, LAI cabotegravir–rilpivirine
was superior to TLD for maintaining virological suppression, with no new safety concerns
observed. These findings sup...